SemBioSys - In Development

By: Sembiosys  09-12-2011
Keywords: Pharmaceutical Products, Agricultural Biotechnology, Nutritional Oils

Additional Applications of Our Technology

Due to the flexibility of our plant technology, a wide range of potential applications exist. We have chosen to work on products for which the inherent benefits of our technology, including scalability and economics, enable them to be commercially viable. The following non-pharmaceutical products have shorter development times than our pharmaceutical products and have the potential to enhance our financial position as we pursue our pharmaceutical products.

Industrial Enzymes

SemBioSys has developed safflower-produced chymosin (also called rennin), a natural enzyme used in the production of cheese. We have also developed an extraction process that we believe will allow for the production of chymosin in plants at significantly lower costs than current production systems.

Nutritional Oils

Nutrition and healthy eating are hot topics and products supplemented with essential fatty acids are popping up everywhere. SemBioSys, in conjunction with Arcadia Biosciences, is developing safflower oil rich in the omega-6 fatty acid Gamma Linolenic Acid (GLA). As a nutrient with proven health benefits, GLA is currently used in supplements, nutraceuticals and functional foods.

Agricultural Biotechnology

There are many opportunities to apply our technology in the field of agricultural biotechnology. These include the areas of animal vaccines and aquaculture.

Animal Vaccines

The animal health industry must continually develop effective treatments, typically vaccines, to prevent economic losses due to disease. SemBioSys' technology can be applied to facilitate the production, purification, and delivery of animal vaccine formulations. Our technology can be applied to the development of alternate vaccination routes (nasal, oral or transdermal) and may improve the presentation and immunological response to antigens when administered to animals.


The aquaculture industry is a highly competitive market characterized by high-density production which makes it susceptible to disease. Producers are continually searching for new ways to improve their economics, increase growth rates and reduce the impact of disease, which can wipe out an entire region's production in one season. SemBioSys' technology can be used to produce feed additives that promote growth and enhance survival against viral disease, while offering producers enhanced yield and production economics at a substantially reduced cost.

Keywords: Agricultural Biotechnology, Nutritional Oils, Pharmaceutical Products,

Contact Sembiosys

Email - none provided

Print this page

Other products and services from Sembiosys


SemBioSys - Diabetes

We believe our plant-made insulin will offer dramatic reductions in capital and operating costs and provide an accessible source of insulin to meet this exploding demand. Discussions with the US Food and Drug Administration have confirmed that safflower-produced insulin is eligible to follow a shortened drug approval process.


SemBioSys - Personal Care

SemBioSys has developed an all-natural process to extract oilbodies from safflower seeds resulting in a base emulsion with superior hydration, skin conditioning and moisturization properties compared to traditional ingredients such as petrolatum or chemical and animal byproducts. Beyond the benefits as a personal care product ingredient, oilbodies hold the potential to act as a carrier and delivery system for pharmaceutical products.


SemBioSys - Technology

Our technology is built on two basic capabilities: the use of genetic engineering to attach high-value proteins to (the structures used by seeds to store oil); and extraction of oilbodies from seeds in a cost-effective manner. For the production of high-value proteins, we believe that our plant technology is unique among transgenic systems as it addresses both production and purification challenges.


SemBioSys - Heart Attack and Stroke

Cardiovascular diseases, including heart attack and stroke, are the leading causes of mortality in developed nations and by 2010, are projected to become the leading cause of mortality worldwide. Apo AI is the major protein associated with high density lipoprotein, or "good cholesterol", whose function is to remove excess cholesterol from arteries.


SemBioSys - Overview

The same advantages that drive our pharmaceutical opportunities also apply to our non-pharmaceutical products, which include topical ingredients that are delivering innovation and value for personal care producers, nutritional oils for use in a variety of consumer goods, and applications for agricultural biotechnology.